Related Experiment Video
Updated: Jul 18, 2026
09:29
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Successful gastrointestinal cancer drug development
1University of California-Los Angeles GI Oncology Program, UCLA School of Medicine, Los Angeles, CA 90095, USA. jrhecht@mednet.ucla.edu
Seminars in Oncology
|December 21, 2006
Summary
Analyzing gastrointestinal malignancy drug development reveals key lessons from both successes and failures. Understanding these insights is crucial for optimizing future therapeutic strategies and resource allocation.
Area of Science:
- Oncology
- Gastroenterology
- Pharmacology
Background:
- Over the past decade, numerous drugs for gastrointestinal malignancies have been approved, yet many others have failed, incurring significant financial and patient costs.
- Effective drug development requires identifying active compounds and determining optimal administration strategies (manner and population) to maximize efficacy and minimize toxicity.
Purpose of the Study:
- To examine successful and unsuccessful drug development cases in gastrointestinal oncology.
- To apply lessons learned from past drug development to improve current and future strategies.
Main Methods:
- Review of approved drugs for gastrointestinal malignancies over the last 10 years.
- Analysis of case studies including successful agents (e.g., imatinib), delayed successes (e.g., oxaliplatin), and failures (e.g., SU-5416).
Main Results:
- Drug development for gastrointestinal cancers is complex, with both notable successes and costly failures.
- Specific examples highlight the importance of strategic development and market positioning.
Conclusions:
- Lessons from imatinib, oxaliplatin, and SU-5416 offer valuable insights for optimizing future drug development in gastrointestinal oncology.
- A thorough examination of past development processes is essential for efficient and effective therapeutic advancements.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:20Gastrointestinal Motility Disorders
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...